Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioHarvest Sciences Inc. (BHST) disrupts biotechnology with its patented Botanical Synthesis platform—think yeast fermentation, but for whole-plant molecules. Investors scanning BioHarvest Sciences SEC filings want clarity on how nutraceutical sales and CDMO contracts convert breakthrough science into revenue, yet Form 10-K and 10-Q sections on R&D, scalability, and regulatory pathways can feel impenetrable.
Stock Titan delivers BioHarvest Sciences SEC filings explained simply. Our AI reads every line, then surfaces what matters: segment revenue shifts, patent portfolio updates, and consumption trends in cardiovascular health products found inside the BioHarvest Sciences annual report 10-K simplified. Need to track management moves? Receive BioHarvest Sciences Form 4 insider transactions real-time—no more manual EDGAR searches for BioHarvest Sciences insider trading Form 4 transactions.
Whether you’re researching a BioHarvest Sciences quarterly earnings report 10-Q filing, verifying BioHarvest Sciences proxy statement executive compensation, or parsing a sudden BioHarvest Sciences 8-K material events explained, the platform keeps you informed. Key features include:
- AI-powered summaries that translate dense disclosures into plain language, perfect for understanding BioHarvest Sciences SEC documents with AI.
- Real-time alerts the moment a BioHarvest Sciences executive stock transactions Form 4 posts.
- Unified access to every filing type—from R&D milestone 8-Ks to earnings report filing analysis—updated within seconds of EDGAR release.
Analysts use these insights to:
- Compare quarter-over-quarter nutraceutical margins
- Monitor insider buying ahead of new CDMO contracts
- Validate capital needs against large-scale bioreactor expansion
Skip the 200-page PDFs. Stock Titan’s AI-powered analysis distills BioHarvest Sciences disclosures into clear, decision-ready insights before the market opens.
BioHarvest Sciences Inc. (BHST) has filed a Form S-8 registering securities that may be issued under its 2025 Equity Incentive Plan. The company is a Canadian non-accelerated filer, smaller reporting registrant and emerging-growth company. O’Neill Law LLP is named as agent for service. Documents incorporated by reference include the FY-2024 Form 40-F, various Form 6-Ks and the Form 8-A describing BHST’s common shares. Exhibits comprise the legal opinion, auditor consent, the plan document, powers of attorney and the filing-fee table.
The statement contains customary indemnification provisions for directors and officers under British Columbia’s Business Corporations Act and standard undertakings to update or withdraw unsold shares. The filing was signed on 22 July 2025 by CEO Ilan Sobel, CFO Bar Dichter and the full board, with a U.S. representative signing in Nevada.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
